Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches

L. Ereshefsky, Stephen R Saklad, M. W. Jann, C. M. Davis, A. Richards, D. R. Seidel

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities. Analytic methods for neuroleptic assays, including chromatographic, radioreceptor, nuclear magnetic resonance, and radioimmunoassay techniques, are briefly reviewed. Elucidation of depot neuroleptic multicompartment kinetics utilizing nonlinear mixed-effects modeling and the usefulness of these data in interpreting plasma levels are discussed. The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and response. Clinical advantages resulting from the availability of more depot neuroleptics are discussed.

Original languageEnglish (US)
Pages (from-to)50-59
Number of pages10
JournalJournal of Clinical Psychiatry
Volume45
Issue number5 II
StatePublished - 1984

Fingerprint

Antipsychotic Agents
Pharmacokinetics
Dosage Forms
Haloperidol
Therapeutics
Radioimmunoassay
Magnetic Resonance Spectroscopy
Guidelines
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Ereshefsky, L., Saklad, S. R., Jann, M. W., Davis, C. M., Richards, A., & Seidel, D. R. (1984). Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry, 45(5 II), 50-59.

Future of depot neuroleptic therapy : Pharmacokinetic and pharmacodynamic approaches. / Ereshefsky, L.; Saklad, Stephen R; Jann, M. W.; Davis, C. M.; Richards, A.; Seidel, D. R.

In: Journal of Clinical Psychiatry, Vol. 45, No. 5 II, 1984, p. 50-59.

Research output: Contribution to journalArticle

Ereshefsky, L, Saklad, SR, Jann, MW, Davis, CM, Richards, A & Seidel, DR 1984, 'Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches', Journal of Clinical Psychiatry, vol. 45, no. 5 II, pp. 50-59.
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry. 1984;45(5 II):50-59.
Ereshefsky, L. ; Saklad, Stephen R ; Jann, M. W. ; Davis, C. M. ; Richards, A. ; Seidel, D. R. / Future of depot neuroleptic therapy : Pharmacokinetic and pharmacodynamic approaches. In: Journal of Clinical Psychiatry. 1984 ; Vol. 45, No. 5 II. pp. 50-59.
@article{a78b0f551b274be6a90d83b8f49d014a,
title = "Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches",
abstract = "The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities. Analytic methods for neuroleptic assays, including chromatographic, radioreceptor, nuclear magnetic resonance, and radioimmunoassay techniques, are briefly reviewed. Elucidation of depot neuroleptic multicompartment kinetics utilizing nonlinear mixed-effects modeling and the usefulness of these data in interpreting plasma levels are discussed. The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and response. Clinical advantages resulting from the availability of more depot neuroleptics are discussed.",
author = "L. Ereshefsky and Saklad, {Stephen R} and Jann, {M. W.} and Davis, {C. M.} and A. Richards and Seidel, {D. R.}",
year = "1984",
language = "English (US)",
volume = "45",
pages = "50--59",
journal = "The Journal of clinical psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5 II",

}

TY - JOUR

T1 - Future of depot neuroleptic therapy

T2 - Pharmacokinetic and pharmacodynamic approaches

AU - Ereshefsky, L.

AU - Saklad, Stephen R

AU - Jann, M. W.

AU - Davis, C. M.

AU - Richards, A.

AU - Seidel, D. R.

PY - 1984

Y1 - 1984

N2 - The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities. Analytic methods for neuroleptic assays, including chromatographic, radioreceptor, nuclear magnetic resonance, and radioimmunoassay techniques, are briefly reviewed. Elucidation of depot neuroleptic multicompartment kinetics utilizing nonlinear mixed-effects modeling and the usefulness of these data in interpreting plasma levels are discussed. The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and response. Clinical advantages resulting from the availability of more depot neuroleptics are discussed.

AB - The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities. Analytic methods for neuroleptic assays, including chromatographic, radioreceptor, nuclear magnetic resonance, and radioimmunoassay techniques, are briefly reviewed. Elucidation of depot neuroleptic multicompartment kinetics utilizing nonlinear mixed-effects modeling and the usefulness of these data in interpreting plasma levels are discussed. The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and response. Clinical advantages resulting from the availability of more depot neuroleptics are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0021246009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021246009&partnerID=8YFLogxK

M3 - Article

C2 - 6143748

AN - SCOPUS:0021246009

VL - 45

SP - 50

EP - 59

JO - The Journal of clinical psychiatry

JF - The Journal of clinical psychiatry

SN - 0160-6689

IS - 5 II

ER -